Eleanor Garth

Peptides have become one of the most closely watched areas in longevity medicine, attracting growing interest from researchers, clinicians and consumers alike. Yet despite their popularity, the evidence supporting many peptide interventions remains uneven – ranging from established clinical applications to early-stage experimental research and mechanistic hypotheses.

Peptides have become one of the most closely watched areas in longevity medicine, attracting growing interest from researchers, clinicians and consumers alike. Yet despite their popularity, the evidence supporting many peptide interventions remains uneven – ranging from established clinical applications to early-stage experimental research and mechanistic hypotheses.

For all the progress made in lowering cholesterol and reducing cardiovascular risk, medicine still has remarkably few options for removing the cellular damage that accumulates once atherosclerosis is established.